Targeting lifespan regulatory pathways (e.g., Mcl‐1 degradation, PI3K/Akt pathway inhibition, and modulation of cytokines such as HIF‐1α and GM‐CSF) is expected to provide novel therapeutic strategies for tissue infections, cancers, and autoimmune disorders by regulating the survival time of neutrophils and promoting further neutrophil function. The gene discussed is CSF2; the disease is cancer.